ATE96840T1 - Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen. - Google Patents

Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.

Info

Publication number
ATE96840T1
ATE96840T1 AT88311421T AT88311421T ATE96840T1 AT E96840 T1 ATE96840 T1 AT E96840T1 AT 88311421 T AT88311421 T AT 88311421T AT 88311421 T AT88311421 T AT 88311421T AT E96840 T1 ATE96840 T1 AT E96840T1
Authority
AT
Austria
Prior art keywords
vectors
human protein
compositions useful
direct expression
activated human
Prior art date
Application number
AT88311421T
Other languages
English (en)
Inventor
Nils Ulrik Bang
Hartmut Josef Ehrlich
Brian William Grinnell
Stanley Richard Jaskunas Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE96840T1 publication Critical patent/ATE96840T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
AT88311421T 1987-12-04 1988-12-02 Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen. ATE96840T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/129,027 US4992373A (en) 1987-12-04 1987-12-04 Vectors and compounds for direct expression of activated human protein C
EP88311421A EP0319312B1 (de) 1987-12-04 1988-12-02 Für die direkte Expression von aktiviertem menschlichen Protein-C verwendbare Vektoren und Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE96840T1 true ATE96840T1 (de) 1993-11-15

Family

ID=22438133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88311421T ATE96840T1 (de) 1987-12-04 1988-12-02 Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.

Country Status (20)

Country Link
US (1) US4992373A (de)
EP (1) EP0319312B1 (de)
JP (1) JP2749083B2 (de)
KR (1) KR970009081B1 (de)
CN (1) CN1035527A (de)
AR (1) AR245217A1 (de)
AT (1) ATE96840T1 (de)
AU (1) AU610301B2 (de)
CA (1) CA1339938C (de)
DE (1) DE3885419T2 (de)
DK (1) DK672788A (de)
ES (1) ES2059538T3 (de)
HU (1) HU209587B (de)
IE (1) IE61627B1 (de)
IL (1) IL88559A (de)
MX (1) MX166847B (de)
NZ (1) NZ227177A (de)
PT (1) PT89135B (de)
RU (1) RU1830081C (de)
ZA (1) ZA889033B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6437298A (en) * 1987-08-04 1989-02-07 Hiroshi Okamoto Production of c-terminal amidated peptide
CA2064774C (en) * 1989-08-11 2000-01-11 Anur A. Kumar Culture methods for producing activated protein c
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
IE914102A1 (en) * 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
ATE211177T1 (de) * 1991-01-11 2002-01-15 American Nat Red Cross Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
US5464934A (en) * 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5698444A (en) * 1993-12-23 1997-12-16 Eli Lilly And Company Serotonin receptor protein and related nucleic acid compounds
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
US5905185A (en) * 1995-11-30 1999-05-18 Ppl Therapeutics Protein C production in non-human transgenic mammals
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HU224826B1 (en) 1997-04-28 2006-02-28 Lilly Co Eli Activated protein c formulations
ZA984698B (en) * 1997-06-05 2000-02-01 Lilly Co Eli Methods for treating thombotic disorders.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6103524A (en) * 1998-07-30 2000-08-15 Eli Lilly And Company Metabotropic glutamate receptor protein and nucleic acid
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
BR9915572A (pt) 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
JP2003531567A (ja) * 1999-04-30 2003-10-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド チモーゲン活性化系
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
US6420157B1 (en) * 1999-04-30 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Zymogen activation system
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインc誘導体
ES2234807T3 (es) 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
EP1263943A1 (de) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivate
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
AU2002327649A1 (en) 2001-09-19 2003-04-01 Mcmaster University Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
CN101228269A (zh) * 2005-05-24 2008-07-23 阿维斯塔金格兰技术有限公司 用于生产治疗脓毒症的重组人活化蛋白c的、包含密码子优化的方法
EP1913155A4 (de) * 2005-06-23 2009-08-12 Univ British Columbia Polymorphismen in gerinnungsfaktor iii im zusammenhang mit der vorhersage des ergebnisses für den patienten und des ansprechens des patienten auf eine therapie
CN101262879B (zh) * 2005-06-24 2013-04-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用活化的蛋白c
EP2041338A4 (de) * 2006-06-09 2009-09-30 Univ British Columbia Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
EP2199387A1 (de) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US11895994B2 (en) 2019-10-27 2024-02-13 Shanghai Raas Blood Products Co., Ltd. Humanized knock-in mouse expressing human Protein C
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインc配列

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4603105A (en) * 1982-05-27 1986-07-29 Kaplan Donald A Efficient screening methods for low probability variants
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4617265A (en) * 1984-09-19 1986-10-14 Board Of Regents, University Of Texas System Colony blot assay for enterotoxigenic bacteria
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
EP0215548B2 (de) * 1985-06-27 1998-01-07 Zymogenetics, Inc. Expression von Protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
GB8728837D0 (en) * 1987-12-10 1988-01-27 Eaton Corp Semi-automatic mechanical transmission control and control and control method
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c

Also Published As

Publication number Publication date
PT89135A (pt) 1989-12-29
JPH022372A (ja) 1990-01-08
DK672788A (da) 1989-07-28
IL88559A (en) 1994-02-27
IE883612L (en) 1989-06-04
PT89135B (pt) 1994-04-29
MX166847B (es) 1993-02-09
RU1830081C (ru) 1993-07-23
EP0319312A3 (en) 1990-09-19
US4992373A (en) 1991-02-12
ES2059538T3 (es) 1994-11-16
KR890010199A (ko) 1989-08-07
CN1035527A (zh) 1989-09-13
AU610301B2 (en) 1991-05-16
ZA889033B (en) 1990-08-29
IL88559A0 (en) 1989-07-31
HUT50497A (en) 1990-02-28
CA1339938C (en) 1998-07-07
NZ227177A (en) 1990-07-26
EP0319312B1 (de) 1993-11-03
AR245217A1 (es) 1993-12-30
KR970009081B1 (en) 1997-06-05
EP0319312A2 (de) 1989-06-07
DE3885419T2 (de) 1994-03-31
JP2749083B2 (ja) 1998-05-13
IE61627B1 (en) 1994-11-16
HU209587B (en) 1994-08-29
AU2650988A (en) 1989-06-08
DE3885419D1 (de) 1993-12-09
DK672788D0 (da) 1988-12-02

Similar Documents

Publication Publication Date Title
ATE96840T1 (de) Fuer die direkte expression von aktiviertem menschlichen protein-c verwendbare vektoren und zusammensetzungen.
DE3583392D1 (de) Carbonatapatit enthaltendes mittel und die verwendung von carbonatapatit fuer implantate.
DE68927835D1 (de) Ultraschallbehandlung von Tieren
IT1219613B (it) Composizione per il condizionamento e la lucentezza dei capelli
PT86946A (pt) Skin care compositions
DK90089D0 (da) Hudbehandlingspraeparat
IT1190313B (it) Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
DK96787D0 (da) Human vaevs-plasminogenaktivator
DE68913739T2 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
IT8868118A0 (it) Composizione e procedimento per il trattamento e la cura dei capelli
IT1124875B (it) Mezzi per l'attivazione e la disattivazione di innesti
DE3672283D1 (de) Konditionierungsmittel fuer die behandlung von basismaterialien.
DE220574T1 (de) Menschliches interferon-beta2a und interferon-beta2b
DE3850433T2 (de) Allergiebehandlung und Zusammensetzung dafür.
IT1227671B (it) Procedimento e dispositivo per la fabbricazione di copertine di libri
DE68905238T2 (de) Linearisierungsverfahren fuer gleichspannungswandler und durchfuehrung des verfahrens.
IT8820276A0 (it) Procedimento per la sintesi di ossalil_ ed ossamil_idrazidi.
FR2633516B1 (fr) Composition cosmetique pour le traitement des peaux sensibles deshydratees
IT1245733B (it) Procedimento per il trattamento di magnesio e dispositivo per la sua attuazione
IT8721945A0 (it) Procedimento per la profumazione di libri, dispositivo per l'attuazione di detto procedimento
DE3769332D1 (de) Derivate von pyrido-menadion-additionsprodukten und verwendungen davon.
DE69002234D1 (de) Ultraschallbehandlung von teigerzeugnissen.
IT214793Z2 (it) Dispositivo per la spremitura di carniccio ed altri prodotti di conceria.
DE68924337T2 (de) Gelzubereitung und nagelkosmetik.
DE69231660D1 (de) Hla-typisierung von humanen leukozyten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee